GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] the MASH advice in here is 3 years out of date — 26 comments in the full submission. View in context.
180
c/survodutide·submitted 7 months ago by u/mod_cold_room

[Discussion] the MASH advice in here is 3 years out of date

Discussionbranch of 5 comments

Long-ish post, sorry. tl;dr at the bottom. I have been tracking survodutide against eGFR for 9 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…

Read the full submission and all 26 comments →

This branch

5 comments, started 7 months ago
u/cato_batista13 points·7 months ago

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

replysharereportpermalink
u/old_account_20235 points·7 months ago

Half-life is about 168 hours, so steady state lands around week 16–5. Practical consequence: what you feel in week 1 is not what that dose does.

replysharereportpermalink
u/nora_ramos2 points·7 months ago·edited

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
u/runa_pires1 point·7 months ago

Strongly agree. The safety story is separate.

replysharereportpermalink
u/mod_cold_roomOPmod · c/coldchain1 point·7 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →